Becton, Dickinson, Bio-Rad, Bio-Techne, Shimadzu, VWR and Spectris
A review of instrument and laboratory product companies’ stock performance this month.
Danaher, Fluidigm, HORIBA, Pacific Biosciences and Tecan
In spite of the ambiguous global economic environment, calendar year second quarter demand for a majority of large publicly held instrument and lab product companies remained steadfast. Reminiscent of the first quarter, strength was highlighted in the pharmaceutical and certain applied markets, such as food and environmental, especially in China. Despite sturdy demand, sales growth […]
Major US indexes were mixed in August as the Dow Jones Industrial Average and S&P 500 declined 0.2% and 0.1%, respectively, while the NASDAQ advanced 1.0%. The markets continued to face global economic growth uncertainty and were further imperiled by the Federal Reserve’s hawkish tone on increasing interest rates. However, in the US, sturdy employment […]
Agilent Offers Cautious Outlook in Europe Agilent Technologies posted better-than-projected fiscal third quarter organic sales, driven by robust growth in China and continued strength in the food and pharmaceutical markets. Organic sales, which excludes the discontinued NMR business (see IBO 3/31/15), currency and acquisitions, advanced 3% to $1,044 million. Organic growth slowed sequentially due to […]
Illumina Delivers in China Despite continued weakness in Europe, Illumina’s second quarter sales advanced 11.3% to $600.1 million. Results were slightly above company expectations and notably stronger than the first quarter, led by demand for sequencing and microarray consumables, as well as higher genotyping services revenue and improved order execution. Sales for the NIPT business […]
The Dow Jones Industrial Average and S&P 500 traded at record highs in July despite weak economic data. The US economy grew at a tepid 1.2% in the second quarter, well below growth expectations of 2.6%. Specifically, the variance in growth projections was attributed to lower residential and business spending, which dropped 3.2%, the most […]
Total R&D spending for 22 leading publicly held instrument and lab product companies (see table, page 6) increased at a tepid pace in FY15 and declined as a percentage of sales due to restructuring initiatives, cost saving measures as well as sturdier top line growth. Several companies’ R&D expenditures benefited from currency effects, improved product […]
Direct Sales Deliver Biotage Growth First quarter sales for Biotage climbed 10.2%, 9.3% excluding currency, to SEK 158.9 million ($18.8 million = SEK 8.46 = $1). Sales for all major product lines expanded, including double-digit sales growth for sample preparation, purification and industrial products. Continued demand for the Isolera purification system as well as for […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
